Version 01/21/21

NCI National Clinical Trials Network

EA8192

ECOG-ACRIN cancer research group
Reshaping the future of patient care

For Patients with Urothelial Cancer

EA8192 Available Through ECOG-ACRIN Cancer Research Group

Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy

Patient Population

See Section 3.0 for Complete Eligibility Details

- Age ≥ 18 years, adequate lab values, body weight of > 30 kg, life expectancy of ≥ 12 weeks
- Must have diagnosis of high grade upper tract urothelial carcinoma proven by biopsy within 60 days prior to registration with either:
  - ◊ Upper urinary tract mass on cross-sectional imaging
  - ◊ Tumor directly visualized during upper urinary tract endoscopy before referral to medical oncology
- Must not have any component of small cell carcinoma
- Must have no evidence of metastatic disease or clinically enlarged lymph nodes on imaging required within 28 days prior to registration (see protocol for details)
- Must not have another active (or within 2 years) second malignancy other than those permitted per protocol
- Must not have any uncontrolled illness per protocol
- Must not have received prior radiation therapy to ≥ 25% of the bone marrow for other diseases, or prior systemic anthracycline therapy
- Must not have an active autoimmune disease requiring immunosuppressive therapy within 2 years prior to registration or a history of inflammatory bowel disease, systemic lupus erythematosus, Sarcoidosis syndrome, Wegener syndrome or immune-related pneumonitis or interstitial lung disease (see protocol)
- Must not be on or have used immune suppressive medication within 14 days prior to the first dose of MEDI4736 (see protocol for exceptions)
- Must not have a concomitant primary urothelial carcinoma of the bladder and/or urethra
- Must not have prior history of muscle-invasive urothelial carcinoma with/without systemic chemotherapy (T2-4a and/or N1) within 2 years prior to registration
- NYHA class 2B or better (if cardiac history/symptoms)
- No major surgery within 28 days of registration
- No history of allogeneic organ transplantation

Treatment Plan

See Section 5.0 for Complete Treatment Details

Patients will be assigned to a treatment arm based on their baseline renal function; i.e., patients eligible for Cisplatin (creatinine clearance > 50 ml/min) will be randomized to Arm A or B/ patients ineligible for Cisplatin (creatinine clearance > 15 and ≤ 50 ml/min) will be on Arm C

1 cycle = 14 days; repeat for 4 cycles

- **Arm A**– neoadjuvant aMVAC + MEDI4736 (1500 mg IV over 60 mins) prior to radial nephroureterectomy with template lymph node dissection (RNU)
- **Arm B**– neoadjuvant aMVAC prior to radical nephroureterectomy with template lymph node dissection (RNU)
- *NOTE:*
  - ◊ *Cisplatin is 70 mg/m² over at least 2 hours or 35 mg/m² on days 1 and 2*
  - ◊ *aMVAC to be administered per institutional standard; time window is –2/+4 days*

1 cycle = 21 days; repeat for 4 cycles

- **Arm C**- neoadjuvant MEDI4736 (1500 mg) + Gemcitabine (1000 mg/m² IV over 30 mins) prior to radical nephroureterectomy with template lymph node dissection (RNU)

Surgery details (identical on all arms)- patients with continued lack of radiographic presence of metastatic or unresectable disease following neoadjuvant chemotherapy will proceed to nephroureterectomy and lymph node dissection

- The surgery must take place 21-60 days from completion of Step 1 neoadjuvant systemic therapy
- The surgical approach is left at the surgeon's discretion as long as protocol criteria are met

Study Chair:
Jean Hoffman-Censits, MD

Co-Chairs:
Petros Grivas, MD, PhD
Vitaly Margulis, MD

Patient Enrollment

All Sites: Oncology Patient Enrollment Network (OPEN) https://open.ctsu.org

Protocol Information

ECOG-ACRIN Operations-Boston: 857-504-2900, http://ecog-acrin.org (Member Login)

Please Enroll Your Eligible Patients!

EA8192

EA8192 Available Through ECOG-ACRIN Cancer Research Group

Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy

Schema



1. SOC biopsy and upper urinary tract mass on cross sectional imaging or directly visualized during upper tract endoscopy.
2. Cisplatin-Eligible (CrCl > 50) will be randomized between Arms A and B; Cisplatin-Ineligible (CrCl >15 & ≤50, hearing loss grade ≥3, neuropathy grade ≥2, and/or ECOG PS=2) will be assigned to Arm C. See Section 3.2 for full eligibility criteria.
3. aMVAC = accelerated methotrexate, vinblastine, doxorubicin and cisplatin with pegfilgrastim for 4 cycles; each cycle is 14 days.
4. Durvalumab: 1500 mg IV every 28 days in Arm A, 1500 mg IV every 21 days in Arm C.
5. Surgery = Radical nephroureterectomy and lymph node dissection (RNU).
6. Follow up every 3-6 months for 5 years after surgery.